# David Planchard

Source: https://onco.cc/people/david-planchard/  
OnCo record `david-planchard` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer.

## Summary

David Planchard is a medical oncologist at Gustave Roussy (Villejuif) and a member of the IFCT board. He has led or co-led pivotal trials of targeted agents in oncogene-driven non-small cell lung cancer, including BRAF V600E-mutant disease, and contributes to ESMO clinical practice guidelines for metastatic NSCLC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: clinician-scientist; lung cancer; targeted therapy
- Role: Board member (Conseil d'Administration)
- Specialisms: Thoracic oncology; Lung cancer; Targeted therapy

## Sources

- Society page: https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Planchard+D%5BAuthor%5D

## Connected records

- cancers: [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- companies: [Intergroupe Francophone de Cancérologie Thoracique](https://onco.cc/companies/ifct/)
- key papers: [FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer](https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/), [Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC](https://onco.cc/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/david-planchard.json